CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −359 | $317.44 | $114K | 12,729 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −209 | $318.47 | $67K | 12,520 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −86 | $319.69 | $27K | 12,434 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −147 | $320.62 | $47K | 12,287 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −224 | $321.64 | $72K | 12,063 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −245 | $322.86 | $79K | 11,818 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −81 | $323.64 | $26K | 11,737 |
| 2026-04-02 | McLaughlin Melissa Chief Human Resources Officer | Sale 10b5-1 | −8 | $325.49 | $3K | 11,729 |
| 2026-03-05 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −654 | $322.33 | $211K | 20,443 |
| 2026-03-05 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −740 | $323.55 | $239K | 19,703 |
| 2026-03-05 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −510 | $324.59 | $166K | 19,193 |
| 2026-03-05 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −500 | $326.08 | $163K | 18,693 |
| 2026-03-05 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −124 | $321.81 | $40K | 21,103 |
| 2026-03-05 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −233 | $323.25 | $75K | 20,870 |
| 2026-03-05 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −148 | $324.60 | $48K | 20,722 |
| 2026-03-05 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −153 | $326.24 | $50K | 20,569 |
| 2026-03-04 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −106 | $319.03 | $34K | 23,300 |
| 2026-03-04 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −102 | $320.01 | $33K | 23,198 |
| 2026-03-04 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −215 | $320.81 | $69K | 22,983 |
| 2026-03-04 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −289 | $321.82 | $93K | 22,694 |
Page 3 of 41 · 816 trades